BFIM
HRTX icon

Beese Fulmer Investment Management’s Heron Therapeutics HRTX Stock Holding History

Beese Fulmer Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,742
Closed -$26K – 347
2020
Q2 		$26K Buy
+1,742
New +$28.6K ﹤0.01% 381

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Beese Fulmer Investment Management's HRTX Position: Q3 2020 in Review

Beese Fulmer Investment Management sold out of Heron Therapeutics (HRTX) in Q3 2020, closing a stake of 1,742 shares — an estimated $26K sold.

Beese Fulmer Investment Management first reported a position in HRTX in Q2 2020 and held it in 1 quarter. The position peaked at $26K in Q2 2020. 182 funds tracked by Wall St. Rank hold HRTX as of Q3 2020.

  • Beese Fulmer Investment Management reported no remaining Heron Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Beese Fulmer Investment Management sold 1,742 Heron Therapeutics shares in Q3 2020, an estimated $26K.
  • Beese Fulmer Investment Management first reported a position in Heron Therapeutics in Q2 2020 and held it in 1 quarter.
  • Beese Fulmer Investment Management's Heron Therapeutics position peaked at $26K in Q2 2020.
  • 182 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2020.

Based on Beese Fulmer Investment Management's 13F filing for Q3 2020, filed 8 Oct 2020.